Timeline for Farxiga Generics
Farxiga (dapagliflozin) is an oral diabetes medication used to treat type 2 diabetes. When will it become a generic?
Why is Farxiga still under patent?
Farxiga's patent expiration date has not been announced yet. According to DrugPatentWatch.com, the original patent for Farxiga (US Patent 8,233,446) expired on April 15, 2023, but subsequent patents for its use in different indications, combination formulations, or delivery methods are still in force.
Patents Still in Force
Farxiga's patents for its use in treating chronic heart failure with reduced ejection fraction (HFrEF) and its combination with metformin (Farxiga-XL) are still valid. These patents will likely expire in the early 2030s, making way for generic versions of the drug.
When can we expect generics?
While the exact date for generic Farxiga is uncertain, several pharmaceutical companies have submitted Abbreviated New Drug Applications (ANDAs) to the FDA to produce generic versions of the drug. This is a strong indication that generics will be available soon after the relevant patents expire.
Companies Challenging Farxiga's Patents
At least four companies (Torrent, Mylan, Teva, and Sandoz) have challenged some of the patents for Farxiga in court, which may lead to earlier patent expiration or approval of generic versions.
Clinical Data and Patient Experience
As Farxiga generics become available, patients may be concerned about their side effects, efficacy, and potential differences from the branded version. Clinical trials have shown that generic medications perform similarly to their branded counterparts in terms of safety and effectiveness.
Sources:
[1] DrugPatentWatch.com (Farxiga patent details)
[2] FDA (Dapagliflozin and Metformin Hydrochloride Tablets)
Sources:
1. DrugPatentWatch.com - Farxiga patent details
2. FDA - Dapagliflozin and Metformin Hydrochloride Tablets